Generating AI summary…

Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical

Aug 4 (Reuters) - New York City-based Pathos AI will pay $125 million upfront to a subsidiary of Alphamab Oncology for rights to an experimental drug for a type of breast cancer, the Chinese oncology specialist said Tuesday, as it competes with bigger rivals. Triple-negative breast cancer, or TNBC, is an aggressive type of invasive breast cancer that tends to grow and spread faster and has fewer continue reading...